Exact Sciences Stock (NASDAQ:EXAS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$66.41

52W Range

$40.62 - $79.62

50D Avg

$60.96

200D Avg

$58.95

Market Cap

$12.63B

Avg Vol (3M)

$2.64M

Beta

1.27

Div Yield

-

EXAS Company Profile


Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6,500

IPO Date

Feb 01, 2001

Website

EXAS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
International Sales$117.74M$109.91M$77.48M
Product$545.46M$438.65M$365.47M
Service$743.24M$569.94M$409.67M
COVID-19 Testing$58.09M$143.10M$235.83M
Product and Service, Other$136.01M$53.72M$39.92M

Fiscal year ends in Dec 23 | Currency in USD

EXAS Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.50B$2.08B$1.77B
Operating Income$-215.01M$-577.54M$-835.47M
Net Income$-204.15M$-623.51M$-595.63M
EBITDA$-13.13M$-480.09M$-740.47M
Basic EPS$-1.13$-3.54$-3.48
Diluted EPS$-1.13$-3.54$-3.48

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 31, 24 | 8:17 PM
Q1 24May 08, 24 | 12:00 AM
Q4 23Feb 21, 24 | 9:43 PM

Peer Comparison


TickerCompany
GHGuardant Health, Inc.
TMOThermo Fisher Scientific Inc.
DHRDanaher Corporation
CDNACareDx, Inc
NTRANatera, Inc.
AAgilent Technologies, Inc.
TWSTTwist Bioscience Corporation
CSTLCastle Biosciences, Inc.
CRLCharles River Laboratories International, Inc.
ILMNIllumina, Inc.
MYGNMyriad Genetics, Inc.